Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Axsome Therapeutics Inc Market Cap
From what 17 stock analysts predict, the share price for Axsome Therapeutics Inc (AXSM) might increase by 31.76% in the next year. This is based on a 12-month average estimation for AXSM. Price targets go from $105 to $180. The majority of stock analysts believe AXSM is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 17 Wall Street analysts have assigned AXSM 17 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Axsome Therapeutics Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on AXSM. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of AXSM.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $180 | Reiterates | Nov 27, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $180 | Reiterates | Nov 25, 2024 |
| Ami Fadia Needham | Buy | $130 | Reiterates | Nov 13, 2024 |
| Joel Beatty Baird | Outperform | $116 | Maintains | Nov 13, 2024 |
| Ami Fadia Needham | Buy | $130 | Reiterates | Nov 12, 2024 |
| Leonid Timashev RBC Capital | Outperform | $131 | Maintains | Oct 4, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $107 | Reiterates | Sep 20, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $107 | Reiterates | Sep 16, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $107 | Reiterates | Sep 9, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $107 | Reiterates | Sep 6, 2024 |
| Ami Fadia Needham | Buy | $130 | Reiterates | Sep 5, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $180 | Reiterates | Sep 5, 2024 |
| Cerena Chen Wells Fargo | Overweight | $140 | Initiates | Sep 3, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $180 | Reiterates | Aug 22, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $180 | Maintains | Aug 6, 2024 |
| Ami Fadia Needham | Buy | $130 | Reiterates | Aug 6, 2024 |
| Jason Gerberry B of A Securities | Buy | $106 | Upgrade | Aug 6, 2024 |
| Ashwani Verma UBS | Buy | $105 | Maintains | Aug 6, 2024 |
| Leonid Timashev RBC Capital | Outperform | $130 | Maintains | Aug 6, 2024 |
| Ami Fadia Needham | Buy | $130 | Reiterates | Aug 5, 2024 |
When did it IPO
2015
Staff Count
607
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Herriot Tabuteau M.D.
Market Cap
$4.83B
In 2023, AXSM generated $270.6M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that AXSM's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 27 Nov 2024
Sentiment - POSITIVE
Source - Benzinga
Summary - Axsome Therapeutics reported that AXS-12 significantly reduced cataplexy attack frequency in the Phase 3 ENCORE trial, achieving statistical significance (p=0.017) compared to placebo.
Why It Matters - Axsome's positive Phase 3 trial results for AXS-12 enhance its growth prospects, potentially increasing market value and attracting investor interest in the biotech sector.
Wed, 13 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - AXSM reports stronger-than-expected Q3 results, leading to a stock increase, driven by robust sales of Auvelity.
Why It Matters - AXSM's better-than-expected Q3 results and strong Auvelity sales indicate robust financial health, likely boosting investor confidence and stock value.
Tue, 12 Nov 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Axsome Therapeutics reported Q3 2024 revenue of $104.8M, up 81% YoY, but a net loss of $(64.6M). AXS-07 may gain FDA approval in January; AXS-05 shows Alzheimer's potential, but profitability is uncertain.
Why It Matters - Axsome's strong revenue growth contrasts with rising losses, highlighting cash burn risks. FDA approval for AXS-07 could drive future revenue, but competition and profitability concerns persist.
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Axsome Therapeutics, Inc. (NASDAQ:AXSM) will host its Q3 2024 earnings call on November 12, 2024, at 8:00 AM ET, featuring key executives and analysts from various firms.
Why It Matters - Axsome Therapeutics' Q3 earnings call will reveal financial performance and strategic insights, influencing stock valuation and investor sentiment in the biotech sector.
Tue, 12 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Axsome Therapeutics (AXSM) reported a quarterly loss of $1.34 per share, slightly better than the estimated loss of $1.38, and compared to a loss of $1.32 per share a year earlier.
Why It Matters - Axsome's smaller-than-expected quarterly loss suggests improving financial performance, potentially boosting investor confidence and impacting stock valuation positively.
Mon, 11 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Biotech companies AZN, NVAX, AXSM, TBPH, and PRTA are set to report their Q3 2024 results this week. Investors should monitor these announcements for potential market impact.
Why It Matters - Upcoming earnings reports from AZN, NVAX, AXSM, TBPH, and PRTA may impact stock prices, investor sentiment, and market trends in the biotech sector, influencing portfolio strategies.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
